Comparative trifecta outcomes following radical prostatectomy versus focal therapy for localized prostate cancer: Functional and oncologic trade-offs in a contemporary cohort
Organ-specific side effects following curative-intent radiotherapy and radical prostatectomy for non-metastatic prostate cancer: A population-based cohort study
Prognostic value of interim PSMA-PET total tumour volume for overall survival within ENZA-p, a randomised phase 2 trial of enzalutamide versus enzalutamide plus [177Lu] Lu-PSMA-617 (ANZUP1901)
Progression-free survival following primary staging with [¹⁸F]PSMA-1007-PET/ceCT versus Na[¹⁸F]F-PET/ceCT in prostate cancer: Results from the PRISMA-PET randomized controlled trial
Final overall survival results from the EORTC 1333/PEACE-3 trial: Enzalutamide with or without radium-223 in metastatic castration-resistant prostate cancer
Health-related quality of life, pain, and symptomatic skeletal events in the phase 3 PSMAddition study of [177Lu]Lu-PSMA-617 (177Lu-PSMA-617) combined with ADT and ARPI in patients with PSMA-positive mHSPC
Metastasis-directed therapy and standard of care versus standard of care for oligometastatic prostate cancer (WOLVERINE): a systematic review and individual patient data meta-analysis from the X-MET collaboration